Literature DB >> 32386308

Preoperative Topical Estrogen Treatment vs Placebo in 244 Children With Midshaft and Posterior Hypospadias.

Daniela Gorduza1,2, Ingrid Plotton1,3, Laurent Remontet4,5,6, Claire-Lise Gay1,3, Meriem El Jani7,4, Alaa Cheikhelard8, Thomas Blanc8, Alaa El Ghoneimi9, Marc-David Leclair10, Pascal Roy4,6, Fabrice Pirot11,12, Yanis Mimouni7,4, Segolene Gaillard7,4, Pierre Chatelain1,3, Yves Morel1,13, Behrouz Kassai7,4, Pierre Mouriquand1,2,14.   

Abstract

PURPOSE: Urethral fistula and dehiscence are common after hypospadias surgery. Preoperative androgens have been considered to reduce these complications although this consideration is not evidence-based. Dermatologists have reported the benefits of topical estrogens on skin healing. We investigated whether the preoperative use of topical promestriene could reduce healing complications in hypospadias surgery. Our primary objective was to demonstrate a reduction of healing complications with promestriene vs placebo. Impact on reoperations and other complications, clinical tolerance, bone growth, and biological systemic effects of the treatment were also considered.
METHODS: We conducted a prospective, randomized, placebo-controlled, double-blind, parallel group trial between 2011 and 2015 in 4 French centers. One-stage transverse preputial island flap urethroplasty (onlay urethroplasty) was selected for severe hypospadias. Promestriene or placebo was applied on the penis for 2 months prior to surgery. The primary outcome was the presence of postoperative urethral fistula or dehiscence in the first year postsurgery. For safety reasons, hormonal and anatomical screenings were performed.
RESULTS: Out of 241 patients who received surgery, 122 patients were randomized to receive placebo, and 119 patients received promestriene. The primary outcome was unavailable for 11 patients. Healing complications were assessed at 16.4% (19/116) in the placebo vs 14.9% (17/114) in the promestriene arm, and the odds ratio adjusted on center was 0.93 (95% confidence interval 0.45-1.94), P = 0.86. CONCLUSIONS AND RELEVANCE: Although we observed an overall lower risk of complications compared to previous publications, postsurgery complications were not different between promestriene and placebo, because of a lack of power of the study or the inefficacy of promestriene. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  estrogen treatment; healing complications; hypospadias; onlay urethroplasty

Mesh:

Substances:

Year:  2020        PMID: 32386308     DOI: 10.1210/clinem/dgaa231

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  1 in total

Review 1.  Defining the role of pre-operative hormonal therapy in hypospadias.

Authors:  Kiarash Taghavi; Lomani A O'Hagan; Jacqueline K Hewitt; Pierre DE Mouriquand
Journal:  J Paediatr Child Health       Date:  2022-07-06       Impact factor: 1.929

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.